Causal analyses of the impact of comorbid conditions and concomitant medications on response to neoadjuvant chemotherapy in breast cancer: analysis of a multicenter prospective cohort study (CANTO).

Date publication

mai 2025

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie

Tous les auteurs :
Hamy AS, Grandal B, Jochum F, Dumas É, Sella N, Kassara A, Barraud S, Dubois T, Ballesta A, Everhard S, Lemonnier J, Sauzey M, Bertaut A, Blay JY, Cottu P, Tredan O, Joly F, Gougis P, Asselain B, Latouche A, Vaz Luis I, Andre F, Reyal F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40378528

Résumé

The incidence of breast cancer (BC) increases with age, together with the frequency of comorbid conditions and chronic concomitant medications. However, little evidence is available regarding their impact on response to treatment in the neoadjuvant setting.

Mots clés

breast cancer, comorbid conditions, concomitant medications, neoadjuvant chemotherapy

Référence

ESMO Open. 2025 05 15;10(5):104507